International Study Reveals the Cause of Rare Blood Clots Linked to Some COVID-19 Vaccines
An international team of researchers has uncovered the scientific mechanism behind the rare blood clots observed in some recipients of adenovirus-based COVID-19 vaccines, shedding light on a complication that had remained unexplained for years.
Since the start of global vaccination campaigns, a limited number of serious clotting cases were reported following certain vaccines, without a clear explanation of why they occurred or the underlying immune dysfunction responsible.
Researchers from Canada, Australia, and Germany identified the immune error that leads to these complications. They explained that the issue begins with a normal immune response that, in extremely rare circumstances, deviates from its intended target.
The disorder occurs when the immune system mistakenly confuses its viral target with one of the body’s own proteins. As a result, it produces antibodies that attack a natural blood protein known as “platelet factor 4” (PF4), triggering a condition called “vaccine-induced immune thrombotic thrombocytopenia” (VITT).
The study found that a strong structural similarity between a viral protein known as “protein VII” and the human protein PF4 sets the stage for this immune confusion. However, the situation only becomes dangerous if a highly specific genetic mutation occurs in a single immune cell.
The risk of this mutation lies in the fact that it alters just one amino acid, yet this small change is enough to redirect the antibody toward the human protein instead of the viral one. This leads to abnormal platelet activation, causing simultaneous blood clot formation and a reduction in platelet count.
The research team reported finding the same mutation in all analyzed samples from patients who developed these clots. They were also able to reverse the mutation in the laboratory, which eliminated the antibodies’ ability to trigger clotting, strengthening the evidence for a direct causal link.
Professor Theodore Warkentin, Professor Emeritus at McMaster University in Canada and lead author of the study, stated that the discovery provides a precise molecular explanation of how a normal immune response can, in very rare cases, go off course. He added that understanding the cause is a crucial step toward prevention.
This breakthrough answers long-standing questions, including why the condition is associated with adenovirus-based vaccines or natural infections, why it is extremely rare, why its rates differ among populations, and why it tends to appear after the first dose.
The findings also open the door to the development of safer vaccines in the future, as scientists may now be able to redesign viral components to maintain effectiveness while reducing the risk of this rare immune error.
